Duke Cancer Institute
Patient Care
Research Programs
  • Home
  • Programs and Groups
  • Shared Resources
  • Faculty
  • Clinical Trials
  • Tumor Registry
  • Education
  • About DCI

Quick Links

  • Patient Care
  • Giving to DCI
  • Contact Us

Breadcrumbs Navigation

Home > Tumor Registry
Jumbo Large Regular Text:
Print E-mail
Tumor Registry

Tumor Registry 2010

On Other Web Sites

Additional Resources

American Cancer Society – CA-A Cancer Journal for Clinicians (online)
(Cancer Statistics in January/February or March/April issue each year)

Commission on Cancer of the American College of Surgeons

International Association of Cancer Registries

National Cancer Data Base

NCI -- State Cancer Profiles

NCI -- SEER (Surveillance Epidemiology and End Results)

North American Association of Central Cancer Registries (NAACCR)

North Carolina Central Cancer Registry

The mission of the Duke Tumor Registry is to contribute to the knowledge of cancer prevention, diagnosis and treatment and to contribute to improvements in cancer patient management through the collection of complete, accurate and timely cancer data and by ongoing follow up of patients. The registry provides cancer incidence, treatment, and outcome information and trend data for administrative planning and marketing, development of support programs, quality improvement and research activities. Data are submitted to the North Carolina Central Cancer Registry in compliance with state reporting requirements to support statewide improvements in cancer detection and treatment.

Our primary customers are:

  • Administrators/Directors (Planning  and development of new programs)
  • Center for Cancer Survivorship (Survivor events, education events, support programs)
  • Researchers (Case finding for new studies; follow up for ongoing studies)
  • North Carolina Central Cancer Registry (State-mandated reporting)
  • Outside registries (Request diagnostic, treatment, follow up information)

Eileen J. Morgan, MPA, CTR
Director, Duke and Durham Regional Tumor Registry
919-684-0330
eileen.morgan@duke.edu

Iris A. Katz, BA, CTR
Data Specialist
919-257-9487 Data and research requests
iris.katz@duke.edu

Tumor Registrars
Shelley S. Alvey 
Deborah A. Belvin
Debra J. Carroll, CTR
Michelle N. Chatman, AA
Lisa D. Gimber, AA, FHIT, CTR
Sathya N. Kasala, BS, CTR
Deborah L. Mangum, BSW
Cynthia B. Smith, CTR

Administrative Clerk

Denea J. Labajetta, RT

Volume Trends by Type of Case (PDF 17 KB)

Primary Site Distribution for All Cases 1st Seen at Duke in 2010  

A total of 6243 cases (including non-malignant CNS tumors) diagnosed and/or treated at Duke Hospital or in the Duke Physician Diagnostic Clinics (PDC) were added to the registry database for the year 2010.  Almost 82% are analytic cases (newly diagnosed); 54% of the analytic cases were diagnosed elsewhere and referred to Duke for all or part of their initial treatment.  Non-analytic patients (about 18% of all cases) come to Duke for treatment after initial treatment failure or with recurrent disease.

The most common types of cases seen in 2010 were:  Prostate/GU, Digestive, Brain & CNS and Hema/Lymphatic*.

* Hema/Lymphatic (n=785) includes:  Lymphoma, Myeloma, Leukemia and Other Hematologic.


2010 Analytic Case Profile (Analytic = Newly Diagnosed at First Visit to Duke)

Analytic cases (n=5101) are patients either initially diagnosed at Duke or newly diagnosed elsewhere who are referred to Duke for all or part of their initial treatment.  Fifty-four (54%) percent of the analytic cases were referrals to Duke for treatment.

The most common types of analytic cases are Prostate/GU, Digestive, Brain & CNS and Respiratory.  

Note: Patients who come to Duke only for a 2nd opinion consult are not entered into the registry database.

2010 Non-Analytic Case Profile  (Non-Analytic = Recurrent Disease at First Visit to Duke) 

Non-analytic cases (n=1142) were diagnosed elsewhere and received all of their initial treatment prior to coming to Duke.
Treatment at Duke is either for initial treatment failure (progression of disease) or recurrent disease.  Non-analytic cases also include cases diagnosed at autopsy.   

The most common non-analytic cases are Prostate/GU, Hema/Lymphatic*, Brain & CNS and Digestive.

* Hema/Lymphatic (n=209) includes:  Lymphoma, Myeloma, Leukemia and Other Hematologic.

All 2010 Cases by Primary Site--Duke University Hospital Cases 1st Seen in 2010

Primary Site Analytic Non-
Analytic
Total Percent
of
Total
Lip 2 1 3 0.0
Tongue 29 9 38 0.6
Salivary Glands 15 0 15 0.2
Floor of Mouth 8 0 8 0.1
Gum & Other Mouth 12 1 13 0.2
Nasopharynx 9 0 9 0.1
Tonsil 32 1 33 0.5
Oropharynx 6 1 7 0.1
Hypopharynx 6 1 7 0.1
Other Oral Cavity & Pharynx 2 0 2 0.0
Total Oral and Pharynx 121 14 135 2.2
Esophagus 61 14 75 1.2
Stomach 90 9 99 1.6
Small Intestine 27 5 32 0.5
Cecum 29 13 42 0.7
Appendix 9 2 11 0.2
Ascending Colon 32 10 42 0.7
Hepatic Flexur 6 2 8 0.1
Transverse Colon 16 3 19 0.3
Splenic Flexure 6 1 7 0.1
Descending Colon 9 3 12 0.2
Sigmoid Colon 34 26 60 1.0
Large Intestine, NOS 8 16 24 0.4
Total Colon, Excl. Rectum 149 76 225 3.6
Rectosigmoid Junction 13 11 24 0.4
Rectum 93 28 121 1.9
Total Rectum & Rectosigmoid 106 39 145 2.3
Anus, Anal Canal, Anorectum 25 8 33 0.5
Liver 74 3 77 1.2
Intrahepatic Bile Duct 15 0 15 0.2
Total Liver & Intrahepatic Bile Duct 89 3 92 1.5
Gallbladder 15 3 18 0.3
Other Biliary 31 2 33 0.5
Pancreas 181 11 192 3.1
Retroperitoneum 10 3 13 0.2
Peritoneum, Omentum, Mesentery 7 2 9 0.1
Other Digestive Organs 3 1 4 0.1
Total Digestive System 794 176 970 15.5
Nose, Nasal Cav & Middle Ear 14 0 14 0.2
Larynx 28 4 32 0.5
Lung & Bronchus 550 76 626 10.0
Pleura 34 2 36 0.6
Trachea, Mediastinum, & Heart 6 0 6 0.1
Total Respiratory System 632 82 714 11.4
Total Bones & Joints 20 1 21 0.3
Total Soft Tissue 62 11 73 1.2
Melanomas--Skin 282 67 349 5.6
Other Non-Epithelial Skin 18 3 21 0.3
Total Skin 300 70 370 5.9
Total Breast 551 95 646 10.3
Cevix Uteri 33 4 37 0.6
Corpus Uteri 173 8 181 2.9
Uterus, NOS 4 3 7 0.1
Ovary 97 17 114 1.8
Vagina 4 0 4 0.1
Vulva 36 4 40 0.6
Other Female Genital Organs 5 1 6 0.1
Total Female Genital System 352 37 389 6.2
Prostate 521 136 657 10.5
Testis 11 3 14 0.2
Penis 7 0 7 0.1
Other Male Genital Organs 2 2 4 0.1
Total Male Genital System 541 141 682 10.9
Urinary Bladder 76 45 121 1.9
Kidney & Renal Pelvis 165 42 207 3.3
Ureter 11 0 11 0.2
Other Urinary Organs 8 0 8 0.1
Total Urinary System 260 87 347 5.6
Total Eye & Orbit 51 3 54 0.9
Brain 463 155 618 9.9
Cranial Nerves & Other Nerves 173 30 203 3.3
Total Brain & Other Nervous System 636 185 821 13.2
Thyroid 92 7 99 1.6
Other Endocrine Incl. Thymus 66 15 81 1.3
Total Endocrine System 158 22 180 2.9
Hodgkin Lymphoma 36 15 51 0.8
Total Hodgkin Lymphoma 36 15 51 0.8
Nodal NHL 104 60 164 2.6
Extranodal NHL 114 24 138 2.2
Total NHL 218 84 302 4.8
Total Lymphomas 254 99 353 5.7
Total Myeloma 109 34 143 2.3
Acute Lymphocytic 29 10 39 0.6
Chronic Lymphocytic 24 23 47 0.8
Other Lymphocytic 8 1 9 0.1
Total Lymphocytic Leukemia 61 34 95 1.5
Acute Myeloid 76 21 97 1.6
Acute Monocytic 7 0 7 0.1
Chronic Myeloid 13 6 19 0.3
Other Myeloid/Monocytic 2 2 4 0.1
Total Myeloid & Monocytic Leukemia 98 29 127 2.0
Other Acute Leukemia 5 4 9 0.1
Aleukemic, Subleukemic 2 2 4 0.1
Total Other Leukemia 7 6 13 0.2
Total Leukemias 166 69 235 3.8
Other Hematologic (MDS etc) 47 7 54 0.9
Total Ill-Defined & Unknown Primary 47 9 56 0.9
Grand Total 5101 1142 6243 100.0

 

Duke University Hospital--Newly Diagnosed Cases 1st Seen in 2010 Compared with American Cancer Society Estimates of Incidence for 2011 (pdf 74 KB)

Geographic Referral Patterns

State/County Residence of All patients first seen at Duke in 2010:
Overall, 75% of the patients first seen at Duke in 2010 reside in North Carolina.  The top six counties of residence were:  Durham, Wake, Orange, Cumberland, Alamance and Robeson counties.  Of the patients who reside outside North Carolina (25%), the top six states were:  Virginia, South Carolina, Florida, Georgia, West Virginia and Tennessee.

NC map (pdf 140 KB)

US map (pdf 142 KB)

State/County Residence of Analytic patients first seen at Duke in 2010:
Seventy-nine percent (79%) of the Analytic patients (newly diagnosed) reside in North Carolina.  The top six counties of residence were:  Durham, Wake, Orange, Alamance, Cumberland and Robeson counties.  Of the patients who reside outside North Carolina (21%), the top six states were:  Virginia, South Carolina, Florida, West Virginia, Georgia and Tennessee.

State/County Residence of Non-analytic patients first seen at Duke in 2010:
North Carolina residents represent only 60% of the non-analytic patients who come to Duke for treatment of progression or recurrent disease.  This is a significant difference from analytic patients, 75% of whom come from North Carolina.  For non-analytic patients the top six counties of residence were:  Wake, Durham, Mecklenburg, Guilford, Cumberland and Orange counties.  Of the patients who reside outside North Carolina, the top six states were:  Virginia, South Carolina, Georgia, Florida, West Virginia and Tennessee.

Glossary

Analytic = Newly Diagnosed at First Visit to Duke
Cancer/tumor either initially diagnosed at Duke or newly diagnosed elsewhere and referred to Duke for all or part of their initial treatment

Non-Analytic = Recurrent Disease at First Visit to Duke 
Cancer/tumor diagnosed elsewhere and received all initial treatment prior to coming to Duke.  Treatment at Duke is either for initial treatment failure (progression of disease) or recurrent disease.  Non-analytic cases also include cases diagnosed at autopsy.

References

Cancer Statistics, 2012 (CA-A Cancer Journal for Clinicians, 2012; 62:10-29)

Commission on Cancer, Cancer Program Standards 2012.  American College of Surgeons, Chicago, IL.

International Classification of Diseases for Oncology, 3rd Edition, World Health Organization, 2001.

AJCC Cancer Staging Manual, 7TH Edition, American Joint Committee on Cancer, Chicago, IL.  Published by Springer-Verlag, New York, NY, 2010.

Facebook
Twitter
YouTube
Contact Us | Careers | Make a Gift | Site Map
Duke Medicine | Duke School of Medicine | Duke University
Toll-Free: 888-ASK-DUKE (888-275-3853)
Copyright © 2004-2012 Duke University Health System